BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:UF-KURE-BCMA readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of UF-KURE-BCMA\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07611149-3324@assetmemo.bio
DTSTAMP:20261121T010121Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:UF-KURE-BCMA: Phase 1 readout est. (NCT07611149)
DESCRIPTION:UF-KURE-BCMA\, phase 1\, Multiple Myeloma.\nStudy: Study to Eva
 luate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma\nEstimate
 d primary completion: 30 September 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/uf-kure-bcma#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07611149
URL:https://assetmemo.bio/drug/uf-kure-bcma#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
